JBS heads into its August 10 earnings report with short sellers quietly adding exposure and options traders turning more cautious than they have been all year.
The sharpest signal into the print is in options. Put/call ratio has climbed to 0.12, more than two standard deviations above its 20-day average — the most defensive options positioning JBS has seen in the past 52 weeks outside of a single spike to 0.57. That reading is still well below 1.0, meaning calls dominate in absolute terms, but the sudden shift in relative terms is notable. The stock closed at $13.69, down 4.2% on the week despite rallying 12.9% over the prior month, suggesting some of those recent gains are now being hedged.
Short interest tells the same directional story. Borrowed shares have climbed roughly 33% over the past month to around 36.9 million, with the weekly increase running at 11%. The borrow market, however, remains far from stressed — availability is ample at 555%, meaning more than five shares are available to lend for every one currently borrowed, and the cost to borrow has fallen sharply from above 2% in late June to just 0.48%. Short sellers are building positions into earnings, but the lending market gives them plenty of room to do so. The ORTEX short score of 57.4 reflects this: elevated, but not at an extreme.
The analyst debate is a study in contrasting conviction. JP Morgan upgraded JBS to Overweight on July 28 — a notable positive signal — while Barclays trimmed its target to $20 from $21 mid-month, maintaining its own Overweight rating. Both firms still sit well above the current price. Bulls point to the expansion of EBITDA margins from roughly 5% a decade ago to around 9.5% more recently, and to strong brand momentum across Pilgrim's and Just Bare. Bears lean on the structural risks: livestock disease outbreaks, grain cost volatility, and FX exposure across JBS's sprawling global operations. Valuation multiples add another layer of complexity — the data carries a consensus mean price target near $93, which appears inconsistent with the current price and recent analyst targets of $18–$20; the $93 figure should be treated as unreliable, likely reflecting stale data from the prior Brazilian listing.
One ownership detail stands out. Davis Selected Advisers added nearly 14.4 million shares in the quarter ending June, making it the most aggressive accumulator among institutional holders. That's a meaningful position build from a long-only manager, and it runs directly counter to the short interest build that began around the same time.
The August 10 print will test whether the margin profile that underpinned the stock's strong July run can hold against a quarter shaped by commodity pressure and currency headwinds — and whether the JP Morgan upgrade was timed ahead of good news or simply ahead of the release.
See the live data behind this article on ORTEX.
Open JBS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
